Clinical Trials at University of North Carolina at Chapel Hill
As of August 2026, 121 paid clinical trials are recruiting at University of North Carolina at Chapel Hill, located at 101 MANNING DR, CHAPEL HILL, NC 27514-4220, phone (919) 966-4676 in Chapel Hill, North Carolina. Active studies at this site cover conditions such as Breast Cancer, Multiple Myeloma and Obesity. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Chapel Hill
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
Characterization of Doxycycline Pharmacokinetics and Adherence
Developing and Strengthening Cannabis Warnings: Warning Message Testing
Clearance in Primary Ciliary Dyskinesia
Rethinking Early Airway Clearence Therapies
127 clinical trials at University of North Carolina at Chapel Hill
·Clear filters·A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Shield Post-Approval Study Protocol
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Zenith® Fenestrated+ Clinical Study
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Common conditions studied in Chapel Hill
- Breast Cancer (27 active studies)
- Multiple Myeloma (17 active studies)
- Cancer (16 active studies)
- Obesity (11 active studies)
- Ulcerative Colitis (10 active studies)
- Chronic Lymphocytic Leukemia (9 active studies)
Leading research sponsors in Chapel Hill
- University of North Carolina, Chapel Hill
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Children's Oncology Group
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Chapel Hill?
There are approximately 693 recruiting clinical trials in Chapel Hill, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Chapel Hill pay participants?
Most recruiting trials in Chapel Hill compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Chapel Hill?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Chapel Hill?
The most common conditions under active study in Chapel Hill include Breast Cancer (27), Multiple Myeloma (17), Cancer (16), Obesity (11), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Chapel Hill?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Chapel Hill on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Chapel Hill?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Chapel Hill?
Recruiting research sites in Chapel Hill include University of North Carolina at Chapel Hill, University of North Carolina, UNC Lineberger Comprehensive Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Chapel Hill right now?
The largest active categories in Chapel Hill are Cancer & tumors (245), Diabetes & metabolic (38), Cardiovascular (28). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of North Carolina at Chapel Hill?
University of North Carolina at Chapel Hill is located at 101 MANNING DR, CHAPEL HILL, NC 27514-4220. Use the Google Maps link in the intro above to get directions.
How do I contact University of North Carolina at Chapel Hill?
You can reach University of North Carolina at Chapel Hill by phone at (919) 966-4676. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.